CHIP-BCIS3 trial: findings and key considerations regarding Impella CP™ use

Dear Colleague,

Abiomed, part of Johnson & Johnson, supports the open exchange of scientific information and at times will reach out to the clinical community to share our perspective on recent data.

The recently published CHIP-BCIS3 study1 and its hemodynamic sub-study evaluated the use of a micro-axial flow pump (mAFP, Impella CP) during high-risk percutaneous coronary intervention (HR-PCI) in a predominantly urgent population of patients with severe multi-vessel coronary disease, heart failure, and acute coronary syndromes. The trial was conducted solely in the United Kingdom. The primary report found no difference between the mAFP and standard-of-care arms in a hierarchical ranking of endpoints (win ratio). A signal of increased cardiovascular mortality was observed in a non-powered sub-analysis of the trial.

We believe it is important to consider both the insights generated and several acknowledged limitations of this study. The approach and practices followed in the trial warrant evaluation against existing clinical data and current standards of care for patients undergoing HR-PCI with Impella CP. Several clinically relevant questions and key insights stemming from this study include:

  • The primary cause of death during or after PCI remains unreported. The data provided points to worsening heart failure and cardiogenic shock.
  • The HR-PCI strategy deployed in the study had (1) prolonged procedures in the treatment arm, (2) clinically meaningful differences in the revascularization approach between arms, (3) the inability to stage while on Impella™ and (4) limited to no post-PCI management options for hemodynamic support with Impella.
  • The lack of a consistent approach to assess for hemodynamic instability when weaning Impella differed from certain recommendations contained in the Impella CP Instructions for Use (“IFU”), which recommends maintenance of Impella support in the presence of hemodynamic instability.
  • Routine removal of Impella CP in all patients after HR-PCI is not common clinical practice. This was reinforced in the hemodynamic sub-study of CHIP-BCIS3 with zero bailout use of Impella CP despite documenting a mean cardiac index after PCI suggesting worsening and/or developing signs of cardiogenic shock (below 1.7 in the Impella arm and below 1.9 in the standard of care arm).
  • Cardiovascular mortality rates reported in hospital and at 30 days are approximately twice as high as previously reported in the OPTIMUM database2 and PROTECT III registry4.
  • CHIP-BCIS3 was a HR-PCI study and is not applicable to patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). The recommendations for Impella use in AMI-CS are established by ACC/AHA/ESC guidelines, based on existing clinical evidence and the mortality benefit of Impella CP as shown in the DanGer Shock RCT. 

These gaps limit the generalizability of CHIP-BCIS3 findings to individual patients, institutions and treatment pathways and reinforce why the trial should not be used in isolation to alter clinical practice.

Current Evidence Supporting Impella Use 

The clinical evidence supporting Impella spans more than two decades and includes 2,700 studies that include randomized trials, prospective studies, registries, real-world analyses and investigator-led research involving hundreds of thousands of patients worldwide.

In HR-PCI, mechanical circulatory support may facilitate treatment of complex coronary disease while maintaining hemodynamic stability during and after intervention. Impella’s hemodynamic performance has been demonstrated in randomized clinical investigations including CHIP-BCIS3. Evidence generated across these studies has contributed to clinical understanding of HR-PCI, hemodynamic support, complete revascularization strategies and management of patients with cardiogenic shock.

Given the limitations and study design considerations described above, the CHIP-BCIS3 findings should be interpreted in the context of the study's management protocols, which differed in several respects from the Impella CP IFU and common clinical practice for patients who exhibit hemodynamic instability following HR-PCI.

All forms of mechanical circulatory support should be used thoughtfully, with appropriate patient selection and clinical oversight. Misinterpreting or overgeneralizing findings from any individual study risks withholding potentially beneficial treatment options from patients who could otherwise derive clinical benefit.

Abiomed welcomes further analyses of CHIP-BCIS3 to clarify mortality mechanisms, post-procedural management, rescue support and outcomes in relevant patient subgroups. Until those questions are addressed, the trial should be considered within the context of a broader evidence base.

Our shared objective remains unchanged: optimizing care for patients by ensuring that physicians have access to complete and accurate scientific information to make informed treatment decisions.

Sincerely,

Navin K. Kapur, MD, FACC, FSCAI, FAHA

Learn more about Protected PCI with Impella.

Impella Indications For Use

The Impella (intracardiac pump for supporting the left ventricle) is intended for clinical use in cardiology and in cardiac surgery for up to 5 days for the following indications, as well as others:

  • The Impella is a circulatory support system for patients with reduced left ventricular function, e.g., post-cardiotomy, low output syndrome, cardiogenic shock after acute myocardial infarction, or for myocardial protection after acute myocardial infarction
  • The Impella may also be used as a cardiovascular support system during coronary bypass surgery on the beating heart, particularly in patients with limited preoperative ejection fraction with a high risk of postoperative low output syndrome.
  • Support during high risk percutaneous coronary intervention (PCI)
  • Post PCI

References

  1. Perera D, Ryan M, Ezad SM, et al. Left ventricular unloading in high-risk percutaneous coronary intervention. N Engl J Med. 2026;394(18):1779-1789.
  2. OPTIMUM pVAD: Hirai et al. 2023 CCI Journal. https://doi.org/10.1002/ccd.30834 
  3. PROTECT II: O’Neill, W. et al. 2012. Circulation, 126(14), 1717-27. 
  4. PROTECT III (P2-Like): O'Neill W, et al. American Heart Journal. 2022;248, 139-149; PROTECT III (BCIS Like), Data On File 

IMP-8123

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].